氨己烯酸保存条件

Vigabatrin is a drug used to treat epilepsy and infantile spasms that was developed in the 1980s. The treatment was approved in the UK in 1989. On August 21, 2009, the U.S. FDA approved Vigabatrin, a vigabatrin tablet, for monotherapy in children aged 1 month to 2 years old. The potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjuvant treatment for adult patients with refractory complex partial epilepsy (CPS). The global average incidence of epilepsy is about 0.6%, one-third of which are refractory. It is the first FDA-approved drug to treat infantile spasms. In the past two years, more and more children with TSC have effectively controlled epilepsy through the use of vigabatrin, especially infantile spasms. Western countries even use vigabatrin to prevent brain abnormalities in children with TSC who have not yet developed the disease.

In the trial, 25 children were treated with vigabatrin tablets and vigabatrin to observe the efficacy and safety of the drug. The results showed that 2 months after taking the medicine, the total effective rate was 68.0%. A total of 24 cases took the medicine for ≥4 months, and the total effective rate was 70.8%. After taking vigabatrin tablets Vigabatrin, the blood concentration of phenobarbital is lower than the pre-medication level. The serum alanine aminotransferase level was lower than before taking the drug.

In terms of safety, 22 of the children who received treatment had no side effects; 2 cases developed symptoms of mild dizziness and drowsiness early after taking the drug, but these symptoms could be relieved by themselves; 1 case developed severe restlessness and terminated treatment. From experiments, we can see that vigabatrin tablets Vigabatrin have a good effect on children with refractory epilepsy, and children have good tolerance to it.  

Taking vigabatrin tablets and Vigabatrin for treatment will also produce certain side effects or adverse reactions, common ones include: fatigue/drowsiness/headache/dizziness/mental confusion/depression, etc. Before receiving treatment with Vigabatrin, patients should go to the hospital for a detailed examination and strictly take medication according to the doctor's diagnosis and treatment recommendations. 

  The biggest disadvantage of Vigabatrin is its effect on visual field, and patients may suffer from irreversible concentric visual field loss. This side effect is more common in adult patients than in pediatric patients, with an incidence rate of approximately 25%–50% in adult patients, approximately 15% in pediatric patients, and approximately 15%–31% in infants and young children. The time from the start of treatment to the remission of epilepsy is about 12-35 days. The probability of visual impairment during this period is relatively low. It is currently believed that if Vigabatrin is used for more than 12 weeks and there is still no obvious effect, discontinuation of the drug can be considered.

Storage conditions: Store vigabatrin in a dry place at 20-25°C, shielded from light and sealed. Keep medicines out of reach of children.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: